[
  {
    "title": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?",
    "published": 1713182400,
    "posting_price": 65.79971164,
    "close_price": 65.29853058,
    "percent_change": -0.76167668
  },
  {
    "title": "GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA",
    "published": 1713157560,
    "posting_price": 65.79971164,
    "close_price": 65.29853058,
    "percent_change": -0.76167668
  },
  {
    "title": "GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG",
    "published": 1713154920,
    "posting_price": 65.79971164,
    "close_price": 65.29853058,
    "percent_change": -0.76167668
  },
  {
    "title": "Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know",
    "published": 1712959219,
    "posting_price": 66.04067075,
    "close_price": 65.60695648,
    "percent_change": -0.65673814
  },
  {
    "title": "Attractive call buying opportunities for Russell 1000 stocks - JPM",
    "published": 1712839980,
    "posting_price": 65.98283485,
    "close_price": 66.16596222,
    "percent_change": 0.27753789
  },
  {
    "title": "GILD May 31st Options Begin Trading",
    "published": 1712831760,
    "posting_price": 65.98283485,
    "close_price": 66.16596222,
    "percent_change": 0.27753789
  },
  {
    "title": "Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter",
    "published": 1712821740,
    "posting_price": 65.98283485,
    "close_price": 66.16596222,
    "percent_change": 0.27753789
  },
  {
    "title": "Gilead Sciences: Robust HIV Business and Oncology Growth Potential Justify Buy Rating",
    "published": 1712811420,
    "posting_price": 65.98283485,
    "close_price": 66.16596222,
    "percent_change": 0.27753789
  },
  {
    "title": "12 Best Depressed Stocks To Buy in 2024",
    "published": 1712786947,
    "posting_price": 67.23580127,
    "close_price": 65.65514374,
    "percent_change": -2.35091648
  },
  {
    "title": "Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider",
    "published": 1712700919,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "3 Stocks at 52-Week Lows Poised for a Powerful Rebound",
    "published": 1712688017,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "published": 1712666400,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "11 Best Biotech ETFs To Buy",
    "published": 1712662637,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "Madrigal announces US launch of NASH/MASH drug Rezdiffra",
    "published": 1712653680,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "Unusually active option classes on open April 9th",
    "published": 1712652060,
    "posting_price": 66.65751882,
    "close_price": 67.40929413,
    "percent_change": 1.12781772
  },
  {
    "title": "Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024",
    "published": 1712606700,
    "posting_price": 66.55148915,
    "close_price": 66.90809631,
    "percent_change": 0.53583648
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)",
    "published": 1712569860,
    "posting_price": 66.55148915,
    "close_price": 66.90809631,
    "percent_change": 0.53583648
  },
  {
    "title": "Fly Insider: Xilio, Aerovate among week\u00e2\ufffd\ufffd\ufffd\ufffds notable insider trades",
    "published": 1712542680,
    "posting_price": 66.55148915,
    "close_price": 66.90809631,
    "percent_change": 0.53583648
  },
  {
    "title": "Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?",
    "published": 1712541180,
    "posting_price": 66.55148915,
    "close_price": 66.90809631,
    "percent_change": 0.53583648
  },
  {
    "title": "3 No-Brainer Dividend Stocks to Buy in April",
    "published": 1712400540,
    "posting_price": 66.55148915,
    "close_price": 66.90809631,
    "percent_change": 0.53583648
  },
  {
    "title": "Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows",
    "published": 1712320200,
    "posting_price": 67.16833724,
    "close_price": 67.06231689,
    "percent_change": -0.15784275
  },
  {
    "title": "GILD Named 'Top Dividend Stock of the Nasdaq 100' at Dividend Channel With 4.4% Yield",
    "published": 1712298900,
    "posting_price": 67.16833724,
    "close_price": 67.06231689,
    "percent_change": -0.15784275
  },
  {
    "title": "Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space",
    "published": 1712249878,
    "posting_price": 68.66224543,
    "close_price": 67.03340149,
    "percent_change": -2.37225557
  },
  {
    "title": "May 24th Options Now Available For Gilead Sciences (GILD)",
    "published": 1712224920,
    "posting_price": 68.66224543,
    "close_price": 67.03340149,
    "percent_change": -2.37225557
  },
  {
    "title": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
    "published": 1712149210,
    "posting_price": 69.39475708,
    "close_price": 68.32492065,
    "percent_change": -1.54166752
  },
  {
    "title": "10 Health Care Stocks Whale Activity In Today's Session",
    "published": 1712148060,
    "posting_price": 69.39475708,
    "close_price": 68.32492065,
    "percent_change": -1.54166752
  },
  {
    "title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today",
    "published": 1712136780,
    "posting_price": 69.39475708,
    "close_price": 68.32492065,
    "percent_change": -1.54166752
  },
  {
    "title": "Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know",
    "published": 1712095218,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Insider Sell: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)",
    "published": 1712057400,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Gilead Sciences Champions Equal Pay",
    "published": 1712045760,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration",
    "published": 1712042794,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Gilead, Nurix extend research pact for two years",
    "published": 1712042760,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "IN BRIEF: Guild Esports jumps on USD250,000 loan",
    "published": 1712039220,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Nurix Therapeutics announces extension of collaboration with Gilead",
    "published": 1712038380,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "5 Healthcare Stocks to Buy for 2024",
    "published": 1712028660,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "My April Dividend Stock Buys With Yields Up To 12%",
    "published": 1712024220,
    "posting_price": 70.18507229,
    "close_price": 69.48148346,
    "percent_change": -1.00247646
  },
  {
    "title": "Gilead Sciences to Present at Upcoming Investor Conferences",
    "published": 1714507500,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript",
    "published": 1714492889,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "XBI: The 2 Things Biotech Needs To Move Higher",
    "published": 1714489419,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Gilead Sciences Enters Oversold Territory",
    "published": 1714473060,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Gilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology Catalysts",
    "published": 1714456620,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)",
    "published": 1714455240,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)",
    "published": 1714442460,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)",
    "published": 1714441920,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)",
    "published": 1714440780,
    "posting_price": 63.24560188,
    "close_price": 62.84079361,
    "percent_change": -0.64005758
  },
  {
    "title": "Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data",
    "published": 1714384875,
    "posting_price": 62.93718592,
    "close_price": 63.55402756,
    "percent_change": 0.98009091
  },
  {
    "title": "Gilead price target lowered by $4 at Barclays, here's why",
    "published": 1714366140,
    "posting_price": 62.93718592,
    "close_price": 63.55402756,
    "percent_change": 0.98009091
  },
  {
    "title": "Gilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth Uncertainties",
    "published": 1714365960,
    "posting_price": 62.93718592,
    "close_price": 63.55402756,
    "percent_change": 0.98009091
  },
  {
    "title": "Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
    "published": 1714228164,
    "posting_price": 62.93719348,
    "close_price": 63.55403519,
    "percent_change": 0.98009091
  },
  {
    "title": "Amgen\u2019s Blincyto data send Cullinan higher",
    "published": 1714185660,
    "posting_price": 62.93719348,
    "close_price": 63.55403519,
    "percent_change": 0.98009091
  },
  {
    "title": "Gilead Gives Up Big Gains As Covid Drug Drives Its Beat \u2014 Again",
    "published": 1714148267,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat",
    "published": 1714141440,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Q1 2024 Gilead Sciences Inc Earnings Call",
    "published": 1714133463,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "FDA Approves Biktarvy\u00ae Label Update With Data for Pregnant Adults With HIV",
    "published": 1714132800,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "June 7th Options Now Available For Gilead Sciences (GILD)",
    "published": 1714129860,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "3 Dividend Stocks to Buy at a 52-Week Low in April",
    "published": 1714128540,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences declares $0.77 dividend",
    "published": 1714123800,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead price target lowered by $5 at TD Cowen, here's why",
    "published": 1714117680,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...",
    "published": 1714116900,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead announces FDA approval for updated Biktarvy label",
    "published": 1714116360,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead price target lowered by $2 at RBC Capital, here's why",
    "published": 1714115160,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)",
    "published": 1714114260,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Truist Financial Reaffirms Their Hold Rating on Gilead Sciences (GILD)",
    "published": 1714113060,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences: A Strong Buy on Robust Sales and Promising Future Catalysts",
    "published": 1714112820,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences grows sales and dividend but lowers some guidance",
    "published": 1714110540,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)",
    "published": 1714109460,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences Unusual Options Activity",
    "published": 1714097940,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript",
    "published": 1714095915,
    "posting_price": 63.12994059,
    "close_price": 63.05283356,
    "percent_change": -0.12214019
  },
  {
    "title": "Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say",
    "published": 1714082408,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Beats Earnings Expectations After Rocky Quarter",
    "published": 1714081740,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...",
    "published": 1714081311,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates",
    "published": 1714079703,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again",
    "published": 1714077647,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript",
    "published": 1714076765,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation",
    "published": 1714076074,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead posts quarterly loss, revenue rises 5%",
    "published": 1714075896,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?",
    "published": 1714075667,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences Announces First Quarter 2024 Financial Results",
    "published": 1714075320,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)",
    "published": 1714067356,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges",
    "published": 1714063225,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead: Q1 Earnings Snapshot",
    "published": 1714061719,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead\u2019s quarterly loss is narrower than expected",
    "published": 1714036860,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys",
    "published": 1714032600,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)",
    "published": 1714029660,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024",
    "published": 1714028160,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Options Volatility and Implied Earnings Moves Today, April 25, 2024",
    "published": 1714025160,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus",
    "published": 1714024800,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1",
    "published": 1714015620,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M",
    "published": 1714014540,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead cuts FY24 adjusted EPS view to $3.45-$3.85 from $6.85-$7.25",
    "published": 1714014240,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead reports Q1 adjusted EPS ($1.32), consensus ($1.39)",
    "published": 1714014180,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Gilead options imply 3.2% move in share price post-earnings",
    "published": 1714011540,
    "posting_price": 65.02866762,
    "close_price": 62.90826797,
    "percent_change": -3.2607152
  },
  {
    "title": "Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.",
    "published": 1713983312,
    "posting_price": 64.17086306,
    "close_price": 64.652771,
    "percent_change": 0.75097625
  },
  {
    "title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?",
    "published": 1713964740,
    "posting_price": 64.17086306,
    "close_price": 64.652771,
    "percent_change": 0.75097625
  },
  {
    "title": "Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage",
    "published": 1713963750,
    "posting_price": 64.17086306,
    "close_price": 64.652771,
    "percent_change": 0.75097625
  },
  {
    "title": "HSBC gets more bullish on Gilead, upgrades shares",
    "published": 1713961620,
    "posting_price": 64.17086306,
    "close_price": 64.652771,
    "percent_change": 0.75097625
  },
  {
    "title": "Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus",
    "published": 1713921120,
    "posting_price": 64.17086306,
    "close_price": 64.652771,
    "percent_change": 0.75097625
  },
  {
    "title": "Incyte (INCY) Earnings Expected to Grow: Should You Buy?",
    "published": 1713880863,
    "posting_price": 64.66241035,
    "close_price": 64.60458374,
    "percent_change": -0.08942848
  },
  {
    "title": "3 Potential Biopharma Buyout Targets",
    "published": 1713877968,
    "posting_price": 64.66241035,
    "close_price": 64.60458374,
    "percent_change": -0.08942848
  },
  {
    "title": "Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?",
    "published": 1713862803,
    "posting_price": 64.66241035,
    "close_price": 64.60458374,
    "percent_change": -0.08942848
  },
  {
    "title": "Undervalued Icons: 3 Household Names Trading at Steep Discounts",
    "published": 1713809984,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?",
    "published": 1713808620,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value",
    "published": 1713798248,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts",
    "published": 1713795623,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics",
    "published": 1713791765,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason",
    "published": 1713791083,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Gilead Sciences: Some Signs Of An Impending Bottom",
    "published": 1713787380,
    "posting_price": 64.50820037,
    "close_price": 64.52747345,
    "percent_change": 0.02987695
  },
  {
    "title": "Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know",
    "published": 1713563419,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "Interesting GILD Put And Call Options For July 19th",
    "published": 1713520380,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "FDA Mandates \"Boxed Warning\" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies",
    "published": 1713515400,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)",
    "published": 1713509460,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk",
    "published": 1713503640,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "Hepion ends Phase 2 study for NASH drug due to cash restraints",
    "published": 1713499980,
    "posting_price": 63.85280455,
    "close_price": 64.34435272,
    "percent_change": 0.76981453
  },
  {
    "title": "US FDA mandates label updates on CAR-T cancer therapies",
    "published": 1713479589,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know",
    "published": 1713477620,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Gilead Sciences Publishes 2023 ESG Impact Report",
    "published": 1713462300,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for",
    "published": 1713448899,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value",
    "published": 1713448769,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "ALX Oncology: Trying To Justify The Hype",
    "published": 1713446778,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "What the Options Market Tells Us About Gilead Sciences",
    "published": 1713442800,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Stifel starts Mirum at buy, cites IBATi drug potential",
    "published": 1713433380,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns",
    "published": 1713416820,
    "posting_price": 64.5853096,
    "close_price": 63.7660675,
    "percent_change": -1.26846508
  },
  {
    "title": "GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA",
    "published": 1713333780,
    "posting_price": 64.91300253,
    "close_price": 64.5082016,
    "percent_change": -0.62360531
  },
  {
    "title": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "published": 1713325680,
    "posting_price": 64.91300253,
    "close_price": 64.5082016,
    "percent_change": -0.62360531
  },
  {
    "title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today",
    "published": 1713317700,
    "posting_price": 64.91300253,
    "close_price": 64.5082016,
    "percent_change": -0.62360531
  },
  {
    "title": "Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why",
    "published": 1713273240,
    "posting_price": 65.3467258,
    "close_price": 64.87445068,
    "percent_change": -0.72272193
  },
  {
    "title": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "published": 1713272410,
    "posting_price": 65.3467258,
    "close_price": 64.87445068,
    "percent_change": -0.72272193
  },
  {
    "title": "Pfizer's Doldrums, Just A Bad Case Of COVID-19?",
    "published": 1713258950,
    "posting_price": 65.3467258,
    "close_price": 64.87445068,
    "percent_change": -0.72272193
  }
]